Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. (Q48896363)

16 February 2018

title

Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. (English)

1 reference

16 February 2018

0 references

Nicolas Fayed

1

1 reference

16 February 2018

Pedro J Modrego

series ordinal

2

1 reference

16 February 2018

Guillermo Rojas-Salinas

series ordinal

3

1 reference

16 February 2018

Keyla Aguilar

series ordinal

4

1 reference

16 February 2018

language of work or name

English

0 references

publication date

15 September 2011

1 reference

16 February 2018

American Journal of Alzheimer's Disease & Other Dementias

published in

1 reference

16 February 2018

volume

26

1 reference

16 February 2018

issue

6

1 reference

16 February 2018

page(s)

450-456

1 reference

16 February 2018

cites work

Excitotoxic cell death

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Reduced hippocampal glutamate in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

A review of 1H MR spectroscopy findings in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

The brain's default network: anatomy, function, and relevance to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Screening for dementia with the memory impairment screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Cerebral blood flow and metabolic abnormalities in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Functional alterations in memory networks in early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Magnetic resonance spectroscopy in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

In vivo quantitative proton MRSI study of brain development from childhood to adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Glutamate and the glutamate receptor system: a target for drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Neuronal death in vitro: parallelism between survivability of hippocampal neurones and sustained elevation of cytosolic Ca2+ after exposure to glutamate receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Amyloid deposition is associated with impaired default network function in older persons without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Long-term synaptic plasticity in hippocampal interneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Amyloid-beta decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511421780

21 January 2018

Identifiers

DOI

10.1177/1533317511421780

1 reference

16 February 2018

PubMed ID

21921084

1 reference

16 February 2018